San Diego, CA--March 23, 2010--Mentor Capital, Inc. (Pink Sheets:MNTR) reports its Cancer Immunotherapy Index has been pushed to an all-time high, now recording a 110% annualized growth since inception, following the Health Care Bill approval. The eleven Index companies are some of the prime beneficiaries of the Bill's 12-year exclusive sales period for biological drugs. Amgen (NASDAQ:AMGN) and Roche's Genentech (NASDAQ:GENE) unit, natural acquirers for the CI Index companies and their pipeline products, also advanced on the news.

Patients usually take biologics through injections or intravenously and the biologic process may take $80 million to $150 million to develop and test. They differ from so called small-molecule drugs, in that biologics are derived from or include living cells and more extensive treatments can cost $50,000 per year. The Bill's 12-year exclusivity, rather than seven years as favored by the Obama administration, the AARP and consumer groups, is a nod to the large development cost and clinical rather than pill-like administration of these newer therapies.

The Cancer Immunotherapy Index includes Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), Immunocellular Therapuetics, Ltd. (OTCBB:IMUC), Dendreon (NASDAQ:DNDN), Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL - SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Quantum Immunologics, Inc. a private company.

Mentor Capital, Inc. invests in all companies in the Cancer Immunotherapy Index and significantly overweights its positions in those companies it views with the greatest medical and financial promise. The Index company summaries can be tracked through updates of the Cancer Immunotherapy Index presented at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.

Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top